Regulatable CAR-T cells for safer cancer treatment
Official title: SaefCAR: Regulatable CAR-T cells for safe and effective immunotherapy
Funded at Mabswitch, INC. · NIH-10759600 · Data updated 2026-11-12
This study is testing a new kind of CAR-T cell therapy that can be safely controlled in the body, aiming to provide a better and safer treatment option for people with different types of cancer, especially solid tumors.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mabswitch, INC. NIH-funded |
| Lab location | 1 site (Van Nuys, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $399,958 |
| NIH project number | 1R43CA281387-01A1 |
| Project ID | NIH-10759600 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include patients with hematological cancers or solid tumors who are seeking innovative treatment options.
✕Less likely to help
Patients with cancers that do not express the targeted antigens or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on developing a new type of CAR-T cell therapy that can be regulated in vivo, aiming to improve safety and effectiveness for treating various cancers, especially solid tumors. The approach seeks to address significant issues with current CAR-T therapies, such as severe side effects and loss of effectiveness, by creating a system that allows for rapid and reversible control of T cell activation. Patients may benefit from a more tailored and safer immunotherapy option that minimizes the risk of adverse events while maximizing therapeutic potential.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer and more effective immunotherapy option for treating cancers.
How similar studies have gone: While CAR-T cell therapies have shown success in treating certain hematological cancers, this specific approach of regulatable CAR-T cells is novel and has not been extensively tested.
Where this research is happening
-
Mabswitch, INC.
Van Nuys, United States Active
Researchers
- Principal investigator: Onakunle, Yemi — Mabswitch, INC.
- Study coordinator: Onakunle, Yemi
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.